The estimated Net Worth of Albion Fitzgerald is at least $592 Mille dollars as of 28 August 2020. Mr. Fitzgerald owns over 8,196 units of CohBar Inc stock worth over $403,281 and over the last 6 years he sold CWBR stock worth over $0. In addition, he makes $188,708 as Independent Chairman of the Board at CohBar Inc.
Albion has made over 1 trades of the CohBar Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 8,196 units of CWBR stock worth $3,524 on 28 August 2020.
The largest trade he's ever made was buying 8,196 units of CohBar Inc stock on 28 August 2020 worth over $3,524. On average, Albion trades about 1,639 units every 0 days since 2018. As of 28 August 2020 he still owns at least 937,863 units of CohBar Inc stock.
You can see the complete history of Mr. Fitzgerald stock trades at the bottom of the page.
Albion J. Fitzgerald serves as Independent Chairman of the Board of the Company. He has served as a member of our board of directors since May 2014 and was appointed as chairman in July 2014. Mr. Fitzgerald previously served as chief executive officer and chairman of the board of directors of ManageIQ, Inc., a provider of global cloud IT systems management solutions. Mr. Fitzgerald was appointed as a director of ManageIQ in 2007, and served as strategic consultant to the Company from 2007 until April 2012, and as chief executive officer and chairman of the board of directors from April 2012 until its acquisition by Red Hat, Inc. in December 2012. In 1992 Mr. Fitzgerald co-founded Novadigm, Inc. (NASDAQ: NVDM), an international provider of IT systems management solutions to Fortune 500 companies and government agencies with customers in 26 countries, where he invented a cybernetic genome translated from biological models for the autonomic management of global-scale IT networks. He served as its chairman and chief technology officer from 1992 and chief executive officer from 1995 until its acquisition by Hewlett Packard in 2004. Prior to Novadigm, Mr. Fitzgerald founded and served as chief executive officer of Telemetrix, Inc., a provider of enterprise IT systems and network management solutions to Fortune 500 companies. From 1980 to 1989, Mr. Fitzgerald was a strategic technology consultant to New York University responsible for architecting, building and managing the university’s computer center and campus-wide multi-media network. Mr. Fitzgerald began his technology career at IBM in 1966. Our board of directors believes that Mr. Fitzgerald’s extensive experience in founding, funding and building emerging technology companies, the depth of his technology and business expertise, and his relevant experience as a director and officer of a publicly-traded enterprise software company make him a valuable contributor to our board of directors.
As the Independent Chairman of the Board of CohBar Inc, the total compensation of Albion Fitzgerald at CohBar Inc is $188,708. There are 9 executives at CohBar Inc getting paid more, with Steven Engle having the highest compensation of $2,410,850.
Albion Fitzgerald is 71, he's been the Independent Chairman of the Board of CohBar Inc since 2014. There are no older and 13 younger executives at CohBar Inc.
Albion's mailing address filed with the SEC is C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK, CA, 94025.
Over the last 7 years, insiders at CohBar Inc have traded over $0 worth of CohBar Inc stock and bought 586,523 units worth $136,480 . The most active insiders traders include Misha Petkevich, Kenneth C Cundy e Jon Leland Stern. On average, CohBar Inc executives and independent directors trade stock every 22 days with the average trade being worth of $9,727. The most recent stock trade was executed by David Greenwood on 1 November 2021, trading 20,000 units of CWBR stock currently worth $8,600.
cohbar (otcqx: cwbr and tsxv: cob.u) is the leader in the research and development of mitochondria-based therapeutics (mbts), an emerging class of drugs for the treatment of diseases associated with aging. mbts originate from the discovery of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. this groundbreaking discovery was made by our founders, world leaders in the biology of aging, metabolism and mitochondrial genomics. mbts offer the potential to address a broad range of diseases such as type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders.
CohBar Inc executives and other stock owners filed with the SEC include: